Ibrutinib is an anti-cancer medication classified as a protein kinase inhibitor, primarily used to treat blood cancers like mantle cell lymphoma and chronic lymphocytic leukemia. It works by inhibiting Bruton's tyrosine kinase, a protein essential for cancer cell survival and proliferation. In summary, Ibrutinib is a targeted therapy for specific hematological malignancies.
Ibrutinib inhibits Bruton's tyrosine kinase, disrupting signaling pathways that promote survival and proliferation of malignant B-cells.